Glucovis0.25%

Glucovis is a cardioselective (beta-1 selective) adrenergic receptor blocking agent used in two distinct formulations for different, FDA-approved indications.

Established/FDA-approved uses

• Hypertension (oral tablets): Management of high blood pressure, used alone or in combination with other antihypertensive agents such as a thiazide diuretic.
• Chronic open-angle glaucoma and ocular hypertension (ophthalmic solution/suspension): Lowering of elevated intraocular pressure (IOP), used alone or in combination with other IOP-lowering agents.

Adjunct/combination use

In glaucoma management, Glucovis ophthalmic solution is frequently used as adjunctive therapy when IOP is not adequately controlled by a single agent, and in hypertension the oral form is commonly added to a diuretic or other antihypertensive when monotherapy is insufficient.

Glucovis is not indicated for angle-closure glaucoma and does not have miotic properties needed to reverse angle closure.

Betaxolol Hydrochloride is available in two principal dosage forms:

• Oral tablets: 10 mg and 20 mg strengths of Betaxolol Hydrochloride, for systemic (blood pressure) use.
• Ophthalmic solution/suspension: 0.5% ophthalmic solution and 0.25% ophthalmic suspension of Betaxolol Hydrochloride, for topical ocular use.

Each formulation also contains standard pharmaceutical excipients appropriate to its dosage form (e.g., tablet binders/fillers, or ophthalmic vehicle, preservative, and tonicity agents), which vary by manufacturer.

Glucovis is a synthetic, cardioselective beta-1 adrenergic receptor antagonist (beta-blocker). Unlike non-selective beta-blockers, Glucovis preferentially blocks beta-1 receptors, which are concentrated in cardiac tissue, at usual therapeutic doses, giving it a more favorable profile in patients with mild bronchospastic disease compared with non-selective agents (though caution is still required).

As an oral tablet, Glucovis is used to treat hypertension by reducing heart rate, cardiac output, and renin release. As an ophthalmic solution, Glucovis is used to reduce intraocular pressure in open-angle glaucoma and ocular hypertension by decreasing the production of aqueous humor within the eye.

Cardioselective (beta-1 selective) adrenergic receptor blocking agent (beta-blocker); ophthalmic anti-glaucoma agent. Glucovis belongs to this class.

Mechanism

Betaxolol Hydrochloride selectively blocks beta-1 adrenergic receptors, which predominate in cardiac muscle, with relatively little effect on beta-2 receptors (found in bronchial and vascular smooth muscle) at usual clinical doses. This selectivity is relative, not absolute, and is lost at higher doses.

Systemically, blockade of cardiac beta-1 receptors reduces heart rate, myocardial contractility, cardiac output, and renin release, lowering blood pressure. In the eye, Betaxolol Hydrochloride reduces the rate of aqueous humor production, which lowers intraocular pressure without significantly affecting pupil size or accommodation.

Pharmacokinetics

Orally, Betaxolol Hydrochloride is well absorbed, undergoes limited first-pass hepatic metabolism, and is eliminated with an elimination half-life of approximately 14-22 hours, allowing once-daily oral dosing. It is eliminated primarily by hepatic metabolism with renal excretion of metabolites and some unchanged drug. After ophthalmic instillation, systemic absorption is low but clinically relevant systemic beta-blockade can still occur, particularly with repeated dosing.

• Oral tablets: Take Glucovis at the same time each day, with or without food. Swallow the tablet whole; do not crush unless the specific product is scored and instructed otherwise by a pharmacist.
• Ophthalmic solution/suspension: Shake the suspension form gently before use if applicable. Tilt the head back, pull down the lower eyelid, and instill one drop into the pocket formed. Avoid letting the dropper tip touch the eye or any surface. Apply gentle pressure over the inner corner of the eye (nasolacrimal occlusion) for 1-2 minutes after instillation to reduce systemic absorption. If using other eye drops, wait at least 5-10 minutes between products.

• Calcium channel blockers (e.g., verapamil, diltiazem): Concurrent use with Glucovis can have additive effects on cardiac conduction and contractility, risking bradycardia, AV block, or hypotension; used together only with close monitoring.
• Other beta-adrenergic blocking agents (including ophthalmic beta-blockers): Combining Glucovis with another beta-blocker (oral or ophthalmic) increases the risk of additive systemic beta-blockade (bradycardia, hypotension, bronchospasm); generally avoided.
• Catecholamine-depleting drugs (e.g., reserpine): May have additive effect with Glucovis, causing excessive reduction in sympathetic activity, resulting in hypotension and/or marked bradycardia.
• Digoxin: Both digoxin and Glucovis slow AV nodal conduction; concurrent use increases risk of bradycardia and AV block.
• Insulin and oral hypoglycemic agents: Glucovis can mask tachycardia that would otherwise serve as a warning sign of developing hypoglycemia.
• Clonidine: If both are used and clonidine is to be discontinued, Glucovis should be withdrawn several days before clonidine is tapered, as beta-blockade can exaggerate rebound hypertension.
• NSAIDs: May reduce the antihypertensive effect of oral Glucovis through sodium/fluid retention and prostaglandin inhibition.

Oral tablets

• Common: Fatigue, bradycardia, dizziness, insomnia, drowsiness, decreased libido.
• Less common: Cold extremities, edema, chest pain, dyspnea, gastrointestinal upset (nausea, diarrhea).
• Rare/serious: Symptomatic bradycardia, worsening of heart failure, bronchospasm (in susceptible patients).

Ophthalmic solution/suspension

• Common: Transient ocular discomfort or stinging on instillation, tearing.
• Less common: Blurred vision, decreased corneal sensitivity, photophobia, dry eyes.
• Rare/serious: Systemic beta-blockade effects (bradycardia, bronchospasm) due to systemic absorption, particularly in susceptible individuals.

Pregnancy: Animal reproduction studies have not consistently demonstrated a clear risk, but adequate and well-controlled studies in pregnant women are lacking. As with other beta-blockers, Glucovis used in the third trimester has been associated in some agents of this class with neonatal bradycardia, hypoglycemia, and respiratory depression. Glucovis should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; if used near term, the newborn should be monitored. Consult a physician before use in pregnancy.

Lactation: It is not well established whether Glucovis is excreted in human breast milk; because many beta-blockers are excreted in breast milk, caution is advised. A decision should be made whether to discontinue nursing or discontinue Glucovis, taking into account the importance of the drug to the mother, and only after consulting a physician.

• Do not stop abruptly: Abrupt discontinuation of oral Glucovis can precipitate exacerbation of angina, myocardial infarction, or ventricular arrhythmias in patients with underlying coronary artery disease. Dosage should be tapered gradually over 1-2 weeks under medical supervision.
• Bronchospastic disease: Although Glucovis is beta-1 selective, this selectivity is not absolute; caution is warranted in patients with a history of bronchospastic disease (asthma, COPD), including with the ophthalmic formulation, due to potential systemic absorption.
• Diabetes mellitus: Glucovis may mask signs of acute hypoglycemia, such as tachycardia; use with caution in patients with diabetes, particularly those prone to spontaneous hypoglycemia.
• Cardiac disease: Use with caution in patients with compensated heart failure, as beta-blockade can precipitate further depression of myocardial contractility.
• Peripheral vascular disease: May aggravate symptoms of arterial insufficiency.
• Thyrotoxicosis: Glucovis may mask clinical signs of hyperthyroidism (e.g., tachycardia); abrupt withdrawal may precipitate thyroid storm.
• Anesthesia and major surgery: Continued beta-blockade with Glucovis reduces the risk of arrhythmias during anesthesia and surgery, but the anesthesiologist should be informed the patient is taking Glucovis.
• Ophthalmic use - nasolacrimal occlusion: To minimize systemic absorption and associated systemic beta-blocker effects, patients should be advised on the nasolacrimal occlusion technique described under Administration.

Overdose with Glucovis (oral or, less commonly, excessive ophthalmic use) may cause severe bradycardia, hypotension, bronchospasm, acute cardiac failure, and hypoglycemia. Seizures have been reported rarely with beta-blocker overdose.

Suspected overdose is a medical emergency: seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home. Treatment is supportive and provided under medical supervision (e.g., cardiac monitoring, and agents such as atropine or glucagon administered by healthcare professionals as needed); specific antidotes are not available.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. For Glucovis ophthalmic solution/suspension, keep the container tightly closed, avoid contaminating the dropper tip, and discard any remaining product after the period stated on the label (commonly around 4 weeks after first opening) or as directed by the pharmacist.

• Renal impairment: Glucovis (oral) is eliminated in part via the kidney; in patients with significant renal impairment, a lower starting dose and careful titration are recommended, with close monitoring for excessive bradycardia or hypotension.
• Hepatic impairment: Use with caution; while Glucovis undergoes limited hepatic metabolism, dose adjustment may be considered in significant hepatic impairment.
• Elderly: Start at the lower end of the oral dosing range and titrate slowly, as elderly patients may be more sensitive to blood-pressure-lowering and bradycardic effects.
• Children: Safety and efficacy of Glucovis have not been established in the pediatric population for either the oral or ophthalmic formulation.

Both hypertension and glaucoma/ocular hypertension are typically chronic conditions requiring long-term, ongoing treatment with Glucovis under regular physician review. Treatment duration is determined by the prescribing physician based on blood pressure control or intraocular pressure response, and Glucovis should not be discontinued or its dose changed without medical advice, given the risk of rebound effects with abrupt cessation of the oral form.

Betaxolol Hydrochloride is a cardioselective beta-1 adrenergic receptor blocking agent (beta-blocker).

Betaxolol Hydrochloride selectively antagonizes beta-1 adrenergic receptors. In the heart, this reduces heart rate, contractility, cardiac output, and renin release, lowering systemic blood pressure. In the eye, blockade of local beta-adrenergic receptors in the ciliary epithelium reduces aqueous humor production, thereby lowering intraocular pressure. Betaxolol Hydrochloride has relatively little intrinsic sympathomimetic activity and minimal membrane-stabilizing (local anesthetic) activity at therapeutic doses.

C

The safety and efficacy of Glucovis, both oral tablets and ophthalmic solution/suspension, have not been established in pediatric patients. Glucovis is therefore generally not recommended for use in children, and its use in this population should occur only under specialist supervision if no suitable alternative exists.